Search company, investor...

Freshfields Bruckhaus Deringer

About Freshfields Bruckhaus Deringer

Freshfields Bruckhaus Deringer is a multinational law firms that offers services in antitrust, tax, and intellectual property law. It is based in London, England.

Headquarters Location

65 Fleet Street

London, England, EC4Y 1HT,

United Kingdom

Missing: Freshfields Bruckhaus Deringer's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Freshfields Bruckhaus Deringer's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Freshfields Bruckhaus Deringer News

TME Pharma N : Terms of availability of the preparatory documents for the GM

May 30, 2023

05/25 05/30/2023 | 03:16am EDT Message : MEETING OF SHAREHOLDERS Berlin, Germany, May 30, 2023, 08.00 a.m. CEST - TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 01.30 p.m. CEST on June 29, 2023, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands. The annual accounts for the year ending December 31, 2022, and the report of the board of directors for 2022, the convocation to the AGM, the agenda and the explanatory notes to the agenda, the instructions and documents for participation and voting at the AGM are available on the company's website. These documents are also available at the company's offices at Max-Dohrn-Strasse8-10, 10589 Berlin, Germany, for shareholders and persons entitled to attend the meeting who, upon request, will receive a copy free of charge. Under Dutch law and the company's Articles of Association, persons entitled to attend and to vote at the AGM are shareholders of the company (which for the purposes of this notice includes holders of a Dutch law right of usufruct) who (i) were registered as a shareholder in one of the administration records of the intermediaries that are (indirectly) participants in Euroclear France on June 01, 2023 (the Registration Date) after all debit and credit entries have been handled as per the Registration Date and (ii) have notified the company by 05.00 p.m. CEST on June 22, 2023, of their attendance in writing or electronically (contact details are available on the company's website). For more information, please contact: TME Pharma N.V. Investor and Media Relations: NewCap About TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focusedpipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-linedata from the NOX-A12three dose-escalationcohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12in other combinations where the interim results from the triple combination of NOX-A12,radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-linedata with encouraging overall survival and safety profile from its NOX-A12combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12in combination with Merck's Keytruda® and two different chemotherapy regimens as second-linetherapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France and Spain and is in discussion with regulatory authorities in the United States. The company's second clinical-stagedrug candidate, NOX-E36,is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development. Further information can be found at: . TME Pharma® and the TME Pharma logo are registered trademarks. Keytruda® is a registered trademark of Merck Sharp & Dohme Corp. Visit TME Pharma on LinkedIn and Twitter . About the GLORIA Study GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma's planned open-labeltwo-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab- paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward- looking statements." Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. Attachments

Freshfields Bruckhaus Deringer Frequently Asked Questions (FAQ)

  • Where is Freshfields Bruckhaus Deringer's headquarters?

    Freshfields Bruckhaus Deringer's headquarters is located at 65 Fleet Street, London.

  • Who are Freshfields Bruckhaus Deringer's competitors?

    Competitors of Freshfields Bruckhaus Deringer include DLA Piper and 4 more.

Compare Freshfields Bruckhaus Deringer to Competitors

Hyperscale Group Logo
Hyperscale Group

Hyperscale Group is an independent advisory and implementation consultancy that offers services in relation to innovation, digital, futures, strategy, operational excellence, and more. It supports businesses seeking growth and develops strategies to maximize their potential. It was founded in 2017 and is based in London, the United Kingdom.

DLA Piper Logo
DLA Piper

DLA Piper operates as a global law firm. It advises international corporations through start-up companies and university spin-outs on corporate, intellectual property, litigation, regulatory and other issues. It was founded in 2005 and is based in London, United Kingdom.

IP Osgoode Logo
IP Osgoode

IP Osgoode is an independent and authoritative voice which explores legal governance issues at the intersection of intellectual property and technology. In the context of a globalizing legal pluralist landscape, IP Osgoode cultivates interdisciplinary, compraative, and transnational research, collaboration, policy-thinking, and practice. The program's researchers and collaborators from the academy, government, business, and other networks actively engage in a transnational debate.


Manigent is a strategy and risk management consulting firm. It provides solutions for risk-based performance management, enterprise performance management, balanced scorecard, enterprise risk management, operational risk management, and compliance. It delivers solutions to the financial services industry and other regulated industries. It was founded in 2007 and is based in London, United Kingdom.

LawtechUK Logo

LawtechUK helps transform the UK legal sector through technology, delivered through a collaboration between Tech Nation, the LawtechUK Panel, and the Ministry of Justice. It provides leadership, tools, and a targeted work program to help the legal and tech communities. It designs, develops, and delivers a program of work to support the transformation of the legal sector through technology. It was founded in 2019 and is based in London, United Kingdom.

The Register Logo
The Register

The Register is a British technology news and opinion website that provides unbiased information on the information technology sector. The website covers topics including science, technology, culture, and columns by cult authors like the BOFH and Verity Stob. It was founded in 1998 and is based in London, England.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.